Clinical Trial Update: Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports on the efficacy, safety, and tolerability of eluxadoline (brand Viberzi) for diarrhea-predominant irritable bowel syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Viberzi (eluxadoline)

Snippet

Sponsor: Furiex Pharmaceuticals, Inc | Conditions: Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2018-07-30